In conclusion, data acquired in the present study illuminated that APE1‐loaded RCSC‐EVs can promote Erlotinib resistance in NSCLC by promoting the activation of the IL‐6/STAT3 signalling (Figure 7). Here, STAT3 is linked to non-small cell lung carcinoma.